Aplaviroc hydrochloride (Synonyms: AK602 hydrochloride; GSK-873140 hydrochloride; GW-873140 hydrochloride)
目录号: PL04721 纯度: ≥99%
CAS No. :461023-63-2
商品编号 规格 价格 会员价 是否有货 数量
PL04721-1mg 1mg ¥7170.91 请登录
PL04721-5mg 5mg ¥11745.45 请登录
PL04721-10mg 10mg ¥20400.00 请登录
PL04721-25mg 25mg ¥42654.55 请登录
PL04721-50mg 50mg 询价 询价
PL04721-100mg 100mg 询价 询价
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Aplaviroc hydrochloride
中文别名
4-[4-({(3R)-1-Butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1 ,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydro chloride (1:1)
英文名称
Aplaviroc hydrochloride
英文别名
4-[4-({(3r)-1-butyl-3-[(r)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1 ,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic Acid Hydro Chloride (1:1);Aplaviroc hydrochloride
Cas No.
461023-63-2
分子式
C33H44ClN3O6
分子量
614.17
包装储存
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
产品详情
Aplaviroc (AK 602) hydrochloride,SDP的一个衍生物,是 CCR5 的拮抗剂,其对 HIV-1Ba-L, HIV-1JRFL 和 HIV-1MOKW 的 IC50 值为 0.1-0.4 nM。
生物活性
Aplaviroc (AK 602) hydrochloride, a SDP derivative, is a CCR5 antagonist, with IC 50 s of 0.1-0.4 nM for HIV-1 Ba-L , HIV-1 JRFL and HIV-1 MOKW .
性状
Solid
IC50 & Target[1][2]
HIV-1Ba-L 0.4 nM (IC50) HIV-1JRFL
体外研究(In Vitro)
Aplaviroc exerts potent activity against three wild-type R5 HIV-1 strains (HIV-1Ba-L, HIV-1JRFL and HIV-1MOKW) with IC50 values of 0.1 to 0.4 nM. Aplaviroc is substantially more potent than two previously published CCR5 inhibitors, E921/TAK-779 and AK671/SCH-C. Aplaviroc suppresses the infectivity and replication of two HIV-1MDR variants, HIV-1MM and HIV-1JSL, at extremely low concentrations (IC50 values of 0.4 to 0.6 nM). Aplaviroc binds to CCR5 with high affinity. The Kd values thus determined for Aplaviroc, E913, E921/TAK-779, and AK671/SCH-C are 2.9±1.0, 111.7±3.5, 32.2±9.6, and 16.0±1.5 nM, respectively. Aplaviroc potently blocks rgp120/sCD4 binding to CCR5 with an IC50 value of 2.7 nM. These results suggest that the potent activity of Aplaviroc against R5 HIV-1 s
体内研究(In Vivo)
The concentration of Aplaviroc (AK602) reached the maximal concentration immediately after intraperitoneal administration and decreased rapidly.
Aplaviroc (AK602, 60 mg/kg, bid, daily) suppresses R5 HIV-1 viremia in hu-PBMC-NOG mice.
has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
ClinicalTrial
参考文献
[1]. Maeda K, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol. 2004 Aug;78(16):8654-62.
[2]. Hirotomo Nakata, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Virol. 2005 Feb;79(4):2087-96.
溶解度数据
In Vitro: DMSO : 200 mg/mL (325.64 mM; Need ultrasonic)H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2